<DOC>
	<DOCNO>NCT00924079</DOCNO>
	<brief_summary>The purpose study investigate possible response pharmacokinetic property nalbuphine oral formulation healthy volunteer .</brief_summary>
	<brief_title>The Development Oral Nalbuphine Dosage Form</brief_title>
	<detailed_description />
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Normal healthy adult subject 2040 year age . Body weight within 80120 % ideal body weight . Ideal body weight = ( height80 ) 0.7 Acceptable medical history physical examination include : Normal chest Xray ECG result within six month prior Period I dose . No particular clinical significance general disease history within two month prior Period I dose . Acceptable clinical laboratory determination without significant deviation normal value within two month prior Period I dose , include : AST ( SGOT ) ALT ( SGPT ) GamaGT alkaline phosphatase total bilirubin albumin glucose BUN uric acid creatinine total cholesterol triglyceride ( TG ) Acceptable hematology within two month prior study , include hemoglobin , hematocrit , red blood cell , MCV , MCH , MCHC , white blood cell , differential white blood cell platelet . Acceptable urinalysis within two month prior study , include pH , blood , glucose protein . Signed write informed consent participate study . Recent history drug alcohol addiction abuse . A clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine neurologic system ( ) psychiatric disease ( determined clinical investigator ) . History allergic response ( ) nalbuphine relate drug . History clinically significant allergy include drug allergy allergic bronchial asthma . Evidence chronic acute infectious disease . Any clinically significant illness surgery four week prior Period I dose ( determined clinical investigator ) . Taking drug know induce inhibit hepatic drug metabolism within one month prior begin study . Receiving investigational drug within one month prior Period I dose . Taking prescription medication nonprescription medication within two week prior Period I . Donating great 150 ml blood within two month prior Period I dose donate plasma ( e.g. , plasmapheresis ) within 14 day prior Period I dose . All subject advise donate blood four week complete study . Consumption caffeine , xanthinecontaining product ( i.e. , coffee , tea , caffeinecontaining soda , cola chocolate , etc . ) and/or alcohol least 48 hour prior day dose schedule period blood sample collect . Any medical reason determine clinical investigator . Patient pregnant breastfeeding . Women childbearing potential must negative urine pregnancy test Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Analysis plasma concentration nalbuphine</keyword>
</DOC>